{"id":"drospirenone-and-ethinyl-estradiol-tablets","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-15","effect":"Breakthrough bleeding"},{"rate":"2-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"},{"rate":"2-3","effect":"Hypertension"}]},"_chembl":null,"_dailymed":{"setId":"ed92658d-87e3-4b5a-912f-0b51943da5e3","title":"LORYNA (DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS) KIT [BRYANT RANCH PREPACK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Drospirenone is a fourth-generation progestin with antimineralocorticoid and antiandrogenic properties, while ethinyl estradiol is a synthetic estrogen. Together, they inhibit the luteinizing hormone (LH) surge and follicle-stimulating hormone (FSH) secretion, preventing ovulation. The combination also thickens cervical mucus and alters the endometrium to reduce sperm penetration and implantation.","oneSentence":"Drospirenone and ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:25:19.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oral contraception for prevention of pregnancy"},{"name":"Treatment of acne vulgaris (in some formulations)"},{"name":"Treatment of premenstrual dysphoric disorder (PMDD)"}]},"trialDetails":[{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT07340190","phase":"PHASE1","title":"A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Advanced Malignancies","enrollment":24},{"nctId":"NCT07318337","phase":"NA","title":"Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-07-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":60},{"nctId":"NCT07242131","phase":"NA","title":"Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS","status":"RECRUITING","sponsor":"Ege University","startDate":"2025-12-01","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":150},{"nctId":"NCT07181343","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)","status":"COMPLETED","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-05-28","conditions":"Psoriasis (PsO)","enrollment":18},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT05934942","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-08","conditions":"Healthy","enrollment":29},{"nctId":"NCT06608186","phase":"PHASE1, PHASE2","title":"Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!","status":"COMPLETED","sponsor":"Ahmed Saad","startDate":"2024-10-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":50},{"nctId":"NCT06250205","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-02-05","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT05872425","phase":"NA","title":"Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS","status":"COMPLETED","sponsor":"Guangdong Women and Children Hospital","startDate":"2023-02-01","conditions":"PCOS","enrollment":120},{"nctId":"NCT06233071","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®","status":"RECRUITING","sponsor":"Bio-innova Co., Ltd","startDate":"2024-02-13","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT06233058","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-03-05","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT06083935","phase":"PHASE4","title":"Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-11-01","conditions":"Poly Cystic Ovary Syndrome","enrollment":120},{"nctId":"NCT03074045","phase":"PHASE3","title":"LCS16 vs. COC User Satisfaction and Tolerability Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-03-13","conditions":"Contraception","enrollment":145},{"nctId":"NCT03091595","phase":"PHASE2","title":"E4/DRSP Ovarian Function Inhibition Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2017-02-07","conditions":"Prevention of Pregnancy","enrollment":82},{"nctId":"NCT04984070","phase":"NA","title":"Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Depression, Anxiety","enrollment":100},{"nctId":"NCT04278755","phase":"PHASE2","title":"Binge Eating & Birth Control","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-09-24","conditions":"Bulimia Nervosa, Binge Eating, Eating Disorders","enrollment":8},{"nctId":"NCT00413062","phase":"PHASE3","title":"Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Contraception","enrollment":2281},{"nctId":"NCT00511433","phase":"PHASE3","title":"Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Contraception","enrollment":48},{"nctId":"NCT00511199","phase":"PHASE3","title":"Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05-01","conditions":"Contraception","enrollment":2152},{"nctId":"NCT05156879","phase":"PHASE4","title":"Aspirin for the Management of Endometriosis-associated Pelvic Pain","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2021-12-23","conditions":"Pelvic Pain","enrollment":220},{"nctId":"NCT01291004","phase":"PHASE1","title":"A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-01-31","conditions":"Follicle Development, Ovarian Follicle, Follicle Count","enrollment":206},{"nctId":"NCT05135013","phase":"","title":"The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study","status":"UNKNOWN","sponsor":"NewGiza University","startDate":"2021-11-16","conditions":"Observational Study","enrollment":200},{"nctId":"NCT04256200","phase":"PHASE2, PHASE3","title":"Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2017-02-07","conditions":"Endometriosis","enrollment":100},{"nctId":"NCT03890341","phase":"PHASE1","title":"Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-01","conditions":"Healthy","enrollment":""},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":"Biological Availability","enrollment":68},{"nctId":"NCT03843736","phase":"PHASE3","title":"The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-02-21","conditions":"Polycystic Ovary Syndrome","enrollment":200},{"nctId":"NCT02710708","phase":"PHASE4","title":"YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-27","conditions":"Contraception","enrollment":1921},{"nctId":"NCT02957630","phase":"PHASE1, PHASE2","title":"\"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study\"","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-09","conditions":"Contraception, Liver Metabolism, Hemostasis Parameter","enrollment":101},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT03111511","phase":"PHASE1","title":"A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2017-03-27","conditions":"Healthy","enrollment":18},{"nctId":"NCT03126097","phase":"PHASE1","title":"A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-04-13","conditions":"Healthy","enrollment":18},{"nctId":"NCT03124524","phase":"PHASE4","title":"Treatment Choice in Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Adana Numune Training and Research Hospital","startDate":"2015-01-15","conditions":"Primary Dysmenorrhea","enrollment":99},{"nctId":"NCT03037944","phase":"EARLY_PHASE1","title":"Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2016-03-01","conditions":"Adenomyosis","enrollment":32},{"nctId":"NCT02885454","phase":"PHASE1","title":"To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT01902264","phase":"PHASE3","title":"Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-08","conditions":"Contraception","enrollment":34},{"nctId":"NCT02617537","phase":"PHASE3","title":"To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2016-01","conditions":"Dysmenorrhea","enrollment":""},{"nctId":"NCT00818519","phase":"PHASE3","title":"GA YAZ ACNE in China Phase III","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":179},{"nctId":"NCT00283816","phase":"PHASE3","title":"Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2006-01","conditions":"Polycystic Ovary Syndrome","enrollment":36},{"nctId":"NCT01608698","phase":"PHASE4","title":"Comparison of Body Weight Change During Contraception With Belara and Yasmin","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-06","conditions":"Body Weight Changes","enrollment":100},{"nctId":"NCT00185484","phase":"PHASE3","title":"Efficacy and Safety Oral Contraceptive Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":1113},{"nctId":"NCT00651846","phase":"PHASE4","title":"Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT00656981","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":541},{"nctId":"NCT00651469","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":534},{"nctId":"NCT00266032","phase":"PHASE3","title":"Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-12","conditions":"Contraception","enrollment":1166},{"nctId":"NCT00569244","phase":"PHASE3","title":"SH T00186 in the Treatment of Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Primary Dysmenorrhea","enrollment":223},{"nctId":"NCT01257984","phase":"PHASE3","title":"Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-12","conditions":"Contraception","enrollment":508},{"nctId":"NCT01076582","phase":"PHASE3","title":"Comparative Trial in Hormone Withdrawal Associated Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04","conditions":"Oral Contraceptive","enrollment":592},{"nctId":"NCT00673686","phase":"PHASE2","title":"Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-05","conditions":"Contraceptives, Oral","enrollment":105},{"nctId":"NCT02237131","phase":"PHASE4","title":"Continuous Versus Cyclic Oral Contraceptives for Endometriosis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-04","conditions":"Dysmenorrhea, Pelvic Pain, Dyspareunia","enrollment":50},{"nctId":"NCT00468481","phase":"PHASE3","title":"Efficacy and Safety Study for an Oral Contraceptive Containing Folate","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-04","conditions":"Neural Tube Defects, Contraception, Oral Contraceptives (OC)","enrollment":385},{"nctId":"NCT00567164","phase":"PHASE3","title":"Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":"Contraception, Ovulation Inhibition, Contraceptives, Oral","enrollment":1887},{"nctId":"NCT00722800","phase":"PHASE2","title":"A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2008-10","conditions":"Hidradenitis Suppurativa","enrollment":4},{"nctId":"NCT00367276","phase":"PHASE3","title":"Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Healthy","enrollment":221},{"nctId":"NCT01258660","phase":"PHASE1","title":"Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-12","conditions":"Contraception","enrollment":172},{"nctId":"NCT01253174","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-08","conditions":"Contraception","enrollment":48},{"nctId":"NCT01253187","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-10","conditions":"Contraception","enrollment":44},{"nctId":"NCT01185678","phase":"","title":"Data on Oral Contraceptives Compliance in Non Stop Regimen","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Contraception","enrollment":8416},{"nctId":"NCT00722761","phase":"PHASE3","title":"Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-04","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT00819312","phase":"PHASE3","title":"YAZ, Oral Contraceptive Registration in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Contraception","enrollment":675},{"nctId":"NCT01182207","phase":"PHASE1","title":"Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-07","conditions":"Healthy","enrollment":33},{"nctId":"NCT01182194","phase":"PHASE1","title":"Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-06","conditions":"Healthy","enrollment":32},{"nctId":"NCT00593294","phase":"PHASE4","title":"Oral Contraceptive and Cardiovascular Risk in PCOS","status":"COMPLETED","sponsor":"Federico II University","startDate":"2006-01","conditions":"Polycystic Ovary Syndrome","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Drospirenone and Ethinyl Estradiol tablets","genericName":"Drospirenone and Ethinyl Estradiol tablets","companyName":"Hansoh BioMedical R&D Company","companyId":"hansoh-biomedical-r-d-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Drospirenone and ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity. Used for Oral contraception for prevention of pregnancy, Treatment of acne vulgaris (in some formulations), Treatment of premenstrual dysphoric disorder (PMDD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}